April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cumulative Risk Factors May Be Prognostic in Advanced Ovarian Cancer
September 20th 2021In an interview with Dana Chase, MD during the ESMO Congress 2021, Chase discussed unmet needs for frontline advanced ovarian cancer treatment and the retrospective analysis of cumulative risk factors and their potential impact on outcome in these patients.
Read More
First Patients Dosed in New CA125 Antagonist Study in Ovarian Cancer
September 2nd 2021Two international studies of oregovomab in combination with other anticancer therapies for the treatment of previously treated, recurrent ovarian cancer have dose its first patients, and patients are being recruited to receive the drug in a phase 3 study conducted in the United States.
Read More
ATR/PARP Inhibition May Overcome PARP Resistance in High-Grade Serous Ovarian Cancer
August 21st 2021In an interview with Targeted Oncology™, Stephanie L. Wethington, MD, MSc, discussed the modern treatment of high-grade serous ovarian cancer and the study of olaparib plus ceralasertib as a strategy for overcoming resistance to PARP inhibition.
Read More
FDA Grants Fast Track Designation to STRO-002 for Ovarian Cancer
August 18th 2021The FDA has granted a fast track designation to the folate receptor alpha-targeting antibody-drug conjugate, STRO-002, for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.
Read More
Mirvetuximab May Replace Paclitaxel as Standard Therapy for High FRα-Expressing Ovarian Cancer
August 11th 2021In an interview with Targeted Oncology™, David O’Malley, MD, discussed the results from an arm of the phase 2 study of 5 mirvetuximab-containing regimens that were evaluated for the treatment of patients with FRα-positive ovarian cancer.
Read More
I/O Vaccine Maveropepimut-S Shows Encouraging Results in Advanced Recurrent Ovarian Cancer
August 11th 2021Outcomes in patients with advanced recurrent ovarian cancer treated with the novel immunotherapeutic vaccine maveropepimut-S appeared encouraging, according to topline results from the DeCidE1 clinical trial.
Read More
Global Study Explores RAF/MEK/FAK Combo in Recurrent LGSOC, With or Without KRAS Mutations
August 6th 2021In an interview with Targeted Oncology™ following a presentation of the study protocol at the 2021 American Society of Clinical Oncology Annual Meeting, Susana K. Banerjee, PhD, explained the progress of ENGOT-ov60/GOG3052/RAMP 201 in detail.
Read More
Maintenance Vigil I/O Shows Efficacy in HRD-Proficient Advanced Ovarian Cancer
August 6th 2021Rodney P. Rocconi, MD, discusses a subgroup analysis of the phase 2b VITAL study in which the efficacy of maintenance Vigil immunotherapy is explored in patients with newly diagnose advanced ovarian cancer who are homologous recombination proficient.
Watch
PROs Offer More Insight on Tolerability of Adavosertib and Gemcitabine to Guide Phase 3 Trial
July 27th 2021In an interview with Targeted Oncology, Ainhoa Madariaga, MD, explained the similarities between the primary and exploratory analyses of adavosertib and gemcitabine in patients with ovarian cancer as it relates to toxicity.
Read More